Business Context and Reporting Period
Company: Madrigal Pharmaceuticals, Inc. (MDGL)
Filing Type: Form 8-K (Current Report)
Date of Report: January 29, 2026
Event: Entry into a Material Definitive Agreement (First Amendment to the Research, Development, and Commercialization Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.).
Key Financial Metrics
This filing is a Current Report regarding a contractual amendment and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes
- Patent Control: Effective January 29, 2026, Madrigal now holds the full and exclusive right and discretion to control all patent term adjustments and extensions applicable to its product Rezdiffra. This includes patents owned by Roche and those jointly owned.
- Royalty Terms: In consideration for the transfer of patent control, the royalty payable to Roche based on net sales of Rezdiffra will not be reduced until the expiration of certain patent term extensions that have been, or could have been, filed.
Outlook, Risks, and Management Commentary
Management Commentary: The amendment clarifies the allocation of rights regarding intellectual property management for Rezdiffra, shifting control to Madrigal while adjusting the timing of royalty reductions to Roche.
Risks and Contingencies: The filing notes that the summary of the Amendment is qualified in its entirety by reference to the full agreement filed as Exhibit 10.1. Certain portions of the exhibit were omitted pursuant to Regulation S-K.
Investor Verification Checklist
- Review Exhibit 10.1 (First Amendment) for the specific list of patent term extensions affected by the royalty reduction delay.
- Verify the exact expiration dates of the patent term extensions that trigger the resumption of royalty reductions to Roche.
- Confirm the scope of "jointly owned" patents included in the transfer of control.
- Assess the potential impact of delayed royalty reductions on future cash flow projections.